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ABSTRACT
Background: Studies on Trypanosoma cruzi infections 
and histopathologic studies in individuals with Chagas 
disease suggest that ischaemia plays a role in the patho-
genesis of myocardial lesions in the chronic phase of the 
disease. These ischaemic disorders are caused by micro-
circulatory deregulation. Atypical angina is a common 
symptom in patients in the chronic phase of Chagas dis-
ease. In a large number of patients, despite the absence 
of significant angiographic coronary obstructions, the 
occurrence of perfusion abnormalities is documented by 
myocardial scintigraphy during stress, which is reversible 
after rest. Methods: This will be a single-centre, prospective, 
single cohort study with a therapeutic intervention followed 
by a late quantitative re-evaluation of myocardial perfusion 
defects initially detected in patients with Chagas disease 
and angiographically normal coronary arte ries. Myocardial 
perfusion single-photon emission computed tomography 
(SPECT) will be performed before and 90 days after thera-
peutic intervention using Technetium (99mTc) sestamibi as a 
radiotracer and physical stress or vasodilation stimulation 
with dipyridamole. Therapeutic intervention will consist 
of acetylsalicylic acid (single daily dose of 100  mg) with 
verapamil (80  mg b.i.d.; a total daily dose of 160  mg). 
The primary endpoint of the study is a > 50% reduction of 
the area of ischaemic myocardium calculated by the polar 
scintigraphic map. Conclusions: This will be the first study 
of a therapeutic approach to attenuate or reverse ischaemic 
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Study Design
RESUMO
Base Racional e Plano de Estudo Prospectivo para 
Avaliar o Efeito de Terapêutica Antiplaquetária  
e Vasodilatadora Microcirculatória em  
Pacientes com Cardiopatia Chagásica Crônica  
e Distúrbios Microvasculares Coronários
Introdução: Há evidência, embasada por estudos em modelos 
experimentais de infecção pelo Trypanosoma cruzi, e também 
por investigações histopatológicas em humanos com a doença 
de Chagas, de que distúrbios de natureza isquêmica partici-
pem da patogênese de lesões miocárdicas na fase crônica da 
moléstia. Esses distúrbios isquêmicos derivam de desregulação 
microcirculatória. Dor precordial atípica é sintoma comum em 
pacientes na fase crônica da doença de Chagas. Em substancial 
proporção desses pacientes, apesar da inexistência de obstruções 
coronárias angiograficamente detectáveis, documenta-se com 
cintilografia miocárdica a ocorrência de distúrbios perfu-
sionais durante o estresse, que são reversíveis após repouso. 
Métodos: Estudo unicêntrico, prospectivo, de coorte única, com 
intervenção terapêutica seguida de reavaliação quantitativa, após 
90 dias, da área ventricular apresentando alterações perfusionais 
isquêmicas inicialmente detectadas em pacientes cardiopatas cha-
gásicos com coronárias angiograficamente normais. A cintilografia 
miocárdica de perfusão será executada com o método SPECT, antes 
e após 90 dias da intervenção terapêutica, tendo o sestamibi-Tc99m 
como radiotraçador e o esforço físico ou o estímulo vasodilatador 
com dipiridamol como estressores. A intervenção terapêutica 
consistirá de ácido acetilsalicílico (dose de 100 mg diária) 
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myocardial perfusion abnormalities of microvascular origin 
in patients with chronic Chagas disease. 
 
DESCRIPTORS: Chagas disease Myocardial ischaemia. 
Microvascular angina. Acetylsalicylic acid. Verapamil.
associado a verapamil (dose diária de 160 mg, em duas tomadas 
de 80 mg). O desfecho primário do estudo será redução > 50% 
da área ventricular de isquemia miocárdica reversível calculada 
pelo mapa polar da cintilografia miocárdica de perfusão. Con-
clusões: Este é o primeiro estudo de intervenção terapêutica para 
atenuar ou reverter alterações miocárdicas isquêmicas de origem 
microvascular em pacientes com cardiopatia chagásica crônica. 
DESCRITORES: Doença de Chagas. Isquemia miocárdica. An gina 
microvascular. Ácido acetilsalicílico. Verapamil. 
V arious studies have indicated that myocardial isch-aemia, provoked by microcirculatory disorders, is an important pathogenetic mechanism in Chagas 
disease. Recently, two comprehensive publications have 
thoroughly reviewed the topic, and the most relevant 
issues are reported below.1,2
HISTOPATHOLOGICAL STUDIES IN HUMANS
Research performed during acute Chagas disease 
has demonstrated that microcirculatory perivascular 
inflammation is partly responsible for the myocardial 
degeneration observed.3 Other necropsy studies were 
conducted in patients who died during the chronic 
phase of the disease, and those studies have des-
cribed intimal proliferation, luminal constriction and 
intramyocardial arterioles.4 Necropsy studies have in-
dicated that microcirculatory abnormalities, including 
pronounced thickening of the basement membrane in 
capillaries, are caused by a diffusely distributed focal 
myocytolysis in specimens obtained through myocardial 
biopsy.5 The results of several other studies have suppor-
ted the concept that abnormal patterns of vasodilation 
and vasoconstriction produce myocardial lesions in 
patients with Chagas disease.6–9 Focal cell necrosis 
and its immediate consequence, interstitial reparative 
fibrosis, which are detected in chagasic hearts, follow 
the same pattern observed in experimental models of 
myocardial lesion induced by ischaemia and reperfu-
sion. Such considerations suggest that low-intensity and 
short transient microvascular dysfunction are essentially 
implicated in the pathogenesis of chronic Chagas car-
diopathy.10,11 Studies on necrotic tissue correlating the 
presence of apical aneurysms with scores proportional 
to the myocardial mass and to the coronary irrigation 
condition concluded that ischaemia factors inhibited 
typical chagasic lesion formation.12 Other independent 
investigations have suggested that the typical ventricular 
aneurysms present in many patients with chronic 
Chagas cardiopathy may be due to the combination of 
microinfarctions, especially those induced in relatively 
less dense coronary vascular territories and where 
microcirculatory defects may occur through abnormal 
adrenergic hyperstimulation.13 This concept could 
represent a possible physiopathological link between the 
microcirculatory pathogenesis hypotheses and chronic 
Chagas cardiopathy.14
STUDIES ON EXPERIMENTAL MODELS  
OF TRYPANOSOMA CRUZI INFECTION
During the 1970s, histopathologic and histoenzy-
mological studies in Wistar rats chronically infected 
with Trypanosoma cruzi or receiving repetitive injec-
tions of isoproterenol demonstrated similarities between 
the myocardial lesions detected in both experimental 
models. These studies also suggested that myofibrillar 
lesions with ischaemic aspects could be due to cardio-
toxicity caused by excessive catecholamine stimulus.15 
In experimental studies using the murine model of 
the Chagas disease, it was possible to detect, through 
histochemical techniques, myocardial ischaemia associa-
ted with coronary microvascular dysfunction resulting in 
occlusive platelet thrombus.16,17 In those experimental 
models, other structural microcirculatory abnormalities 
that affected intimal proliferation and focal vascular 
constriction were also described.18 Such alterations 
were attributed to endothelial lesions directly linked 
to infection by the parasite19 or indirectly produced by 
cellular immunological mechanisms.20
Microcirculatory alterations provoked by Trypano-
soma cruzi infection may be dependent on excessive 
endothelin production, which inhibits the formation of 
cAMP, induces alveolar spasms and stimulates platelet 
adhesion to the endothelium.21 Another possibility is 
neuraminidase production through trypomastigotes of 
the Trypanosoma cruzi, which removes sialic acid from 
the endothelial surfaces, thus making them vulnerable 
to platelet attack and subsequent local thrombosis.22 
Another physiopathological possibility is increasing 
levels of thromboxane-A2, which is detected in the 
murine model of the Chagas infection, reinforcing the 
tendency for platelet adhesion and aggregation and 
causing localised thromboses.23 
It is well-known that an inflammatory infiltrate typi-
cally found in chagasic hearts causes the production of 
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cytokines capable of inducing abnormal microvascular 
reactivity. A seminal study conducted in a murine model 
of Trypanosoma cruzi infection has demonstrated that 
these dysfunctions can be partially reversed through early 
administration of verapamil. This vasodilation agent has 
antiplatelet activity at the microvascular level, reduces 
mortality during the initial phase of infection, and at-
tenuates the evolution of myocardial lesions during 
the chronic phase.24 Verapamil is capable of reversing 
microvascular dysfunctions (segmental spasms and 
capillary hypoflow) directly visualised when preparing 
cremasteric tissue of rats infected with Trypanosoma 
cruzi.25 Finally, other molecular mechanisms that interfere 
with microcirculatory functionality appear to exist in 
the Chagas cardiomyopathy. For example, calreticulin, a 
calcium-binding protein that is also present in the 
human heart, is capable of modulating the complemen-
tary system and inhibiting angiogenesis.26 
CLINICAL INVESTIGATIONS
Clinical aspects
Initially, various clinical manifestations of chronic 
Chagas disease cardiopathy suggested the involvement 
of myocardial ischaemia in its pathogeneses. A large 
number of patients (20%–50%) have chest pain with 
symptoms (pressure, burning) and locations (retrosternal) 
similar to those with angina; however, the chest pain 
usually does not have a consistent correlation with 
physical stress (it occurs frequently at rest), and in most 
cases, it is not alleviated with the use of nitrates.27 
Simultaneously with these symptoms, many individuals 
with Chagas disease and patients with classic ischaemia 
through coronary obstruction exhibit alterations of the 
ST-segment compatible with myocardial ischaemia as 
well as Q waves indicating myocardial necrosis and 
areas of electric inactivity in the electrocardiography.27–29 
Additionally, analogous to what was verified in patients 
with coronary disease, the presence of regional ven-
tricular dyssynergia is detected in many patients with 
Chagas disease.30 Despite the clinical similarities 
between cardiopathies due to coronary obstruction 
and those due to infection with Trypanosoma cruzi, 
the coronary angiography almost invariably indicates 
angiographically normal coronaries in the latter, that 
is, coronaries without detectable obstructions in the 
epicardial arteries.27,31,32
Macrovascular coronary dysfunction
Even if the angiographically observed coronary 
anatomy appears to be normal in patients with chronic 
Chagas, the functionality of coronary macrocirculation 
may be altered. Therefore, the vasodilation response to 
acetylcholine, which depends on endothelial integrity, 
may be depressed in contrast with the preservation 
of the response to adenosine, without endothelial ac-
tion.33 Another study conducted at this laboratory, using 
quantitative coronary responses to hyperventilation tests 
and nitrate administration in chronic chagasic patients 
with atypical angina.34 Together, these results express 
the occurrence of abnormal regulation of epicardial 
coronary circulation related to endothelial and non-
endothelial dysfunction in patients with chronic Chagas 
cardiopathy manifesting chest pain without coronary 
obstructive lesions observed through coronarography. 
Objective evidence of myocardial perfusion 
dysfunctions in humans with chronic Chagas 
heart disease
In the 1970s, pioneering work by Kuschnir et 
al.,35,36 in Cordoba, Argentina using primitive nuclear 
techniques (measuring global myocardial flow with 
86Rubidium) demonstrated that patients with chronic 
Chagas presented reduced myocardial perfusion at rest 
and also during stimulation due to physical strain, in 
comparison to normal controls, and similarly to those 
with chronic coronary disease.
Several independent studies conducted by vari-
ous investigators using perfusion myocardial scintig-
raphy demonstrated the occurrence of remarkable 
perfusional disorders in the hearts of patients with 
chronic Chagas.32,34,37,38 In those studies, the coronary 
arteries were angiographically normal, and the results 
vehemently attest the possibility of microvascular 
alterations, according to experimental studies.32,34,37,38 
One of those studies conducted in this laboratory 
using 201Thallium as a radiotracer indicated fixed, 
paradoxical and reversible defects in all of the 23 
patients included. While the fixed defects (most likely 
indicating the presence of fibrosis) were mainly 
obser ved in ventricular areas, indicating akinesia and 
dyskinesia, the reversible defects (indicating isch-
aemia induced by physical stress) could be detected 
in eight (35%) patients, usually in ventricular areas 
with normal segmental mobility or with relatively 
little impairment.38 
Another investigation performed in the present 
laboratory using 201Thallium focused on the topographic 
correlation between the perfusion defects detected by the 
single-photon emission computed tomography (SPECT) 
method and the regional contraction abnormalities of 
the left ventricle in 37 patients with various stages of 
chronic Chagas cardiopathy.39 Corroborating the results 
of a previous study, perfusion abnormalities topographi-
cally related to the sites affected by the mobility altera-
tions (apical region and inferior-posterior parts of the 
left ventricle) were detected in 78% of the patients. 
Notably, the reversible defects indicating myocardial 
ischaemia were observed in ventricular segments with 
preserved mobility in five of 12 patients with Chagas 
disease, without any other pathological manifestation 
of cardiopathy (undetermined form). Therefore, for the 
first time, perfusion defects compatible with myocardial 
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ischaemia due to physical strain were detected early 
in chagasic patients (before manifesting cardiopathy), 
suggesting that microvascular dysfunctions precede 
and determine the occurrence of alterations related to 
contractions of the regional ventricle in later phases. 
This concept is particularly reinforced by verifying that 
reversible defects (ischaemic) were predominant precisely 
within myocardial areas where ventricular aneurysms 
usually developed.
The accumulation and retention of 201Thallium, 
which is the radiotracer used in the aforementioned 
studies, are not only affected by the regional flow 
but are also dependent on the metabolic state of 
the myocardial cell. Therefore, it is possible that 
the capture defects detected could be due to cell 
metabolism dysfunction, induced by the inflam-
matory infiltrate and not caused by abnormalities 
of the regional flow. Nevertheless, this hypothesis 
was rejected when a study was conducted in the 
present laboratory with 18 patients with chest pain 
severe enough to undergo coronarography. On this 
occasion, a flow tracer (microspheres marked with 
99mTechnetium) was injected in the left ventricular 
cavity of the 18 patients who did not present coro-
nary obstructions.34 In ten of these patients, perfusion 
defects were detected in 49 of 126 segments of the 
left ventricle (39%). In 19 (40%) of these segments 
with perfusion defects at rest, there was severe 
dyssynergia, most likely indicating extensive regional 
fibrosis. In contrast, the other 60% of the ventricular 
segments with perfusion defects occurred in the areas 
of normal or minimally reduced mobility. Again, this 
finding indicated that microvascular perfusion altera-
tions should precede the development of contractile 
abnormalities, and could be occasionally implicated 
in its genesis. 
The foregoing hypothesis was supported by another 
study conducted in the present study’s laboratories, 
which demonstrated that the reversible ischaemic 
defects became irreversible in some of the patients 
when the perfusion study was repeated after a mean 
of 5.6 years.40 Among the 36 patients initially evalu-
ated, 20 (56%) presented reversible defects involving 
approximately 10.2  ±  9.7% of the ventricular area 
tomographically outlined by perfusion myocardial 
scintigraphy. Another remarkable aspect was that the 
development of irreversibility clearly correlated with 
the loss of ventricular systolic function observed in 36 
patients with Chagas cardiopathy.
Physiopathological consequences and 
opportunities for therapeutic intervention
Based on the evidence presented above, the phys-
iopathological consequence of the microvascular dys-
function (which induces myocardial ischaemia) can be 
identified as the depression of the contractile ventricular 
function. It is possible to hypothesise that at least two 
mechanisms link these two physiopathological expres-
sions of Chagas heart disease. 
The first mechanism consists of a contractile state 
similar to that verified in ischaemic cardiopathies by 
coronary arterial disease with hibernating myocardial, 
when ventricular areas are submitted to chronic hypo-
perfusion. The only research initiative, conducted in 
the present laboratories, tested the hypothesis that the 
dyssynergic ventricular areas could be a consequence 
of myocardial hibernation. That study, which used 
the postextrasystolic potentiation technique during 
radiologic-contrast cineventriculography, demonstrated 
that it was possible to identify contractile reserve in 
many dyssynergic areas; therefore, it is still a viable 
reserve.40,41 However, the hypothesis was not supported; 
the viability hidden by dyssynergia and shown through 
postextrasystolic potentiation could predominate or only 
appear in regions showing reversible perfusion defects 
during myocardial scintigraphy.42 
The second and perhaps most decisive mechanism 
would result in cellular death and consequent repairing 
fibrosis. In this context, there are relevant therapeu-
tic implications potentially capable of attenuating, 
slowing, or even hindering the progression of myocardial 
dysfunction occasioned by ischaemic microcirculatory 
dysfunctions. 
Although therapeutic studies aimed at avoiding 
myocardial ischaemia in chronic chagasic cardiopathy 
have not yet been conducted, some results of indirect 
research may be considered encouraging. Therefore, 
prolonged administration of dipyridamole43 or acute 
isosorbide dinitrate administration44 was associated 
with clear improvement of the left ventricular systolic 
function. Nevertheless, these studies did not demons-
trate that the improvement of ventricular function was 
associated with myocardial ischaemia remission; it 
could simply result from more favourable haemody-
namic conditions due to the effects of dipyridamole 
and dinitrate. 
Therefore, there are still new perspectives for studies 
in which the symptoms and objective signs suggesting 
myocardial ischaemia caused by microvascular dysfunc-
tions are attenuated or even reversed by agents acting 
at the microcirculatory level. This study proposes that 
patients with Chagas disease having the mentioned 
characteristics will have a medium-term follow-up and 
will be treated with the combination of a microvascular 
vasodilator (verapamil) and acetylsalicyclic acid acting 
as the inhibitor of platelet activation and aggregation. 
METHODS
Patients with Chagas disease who will have un-
derwent cardiac catheterism at the Haemodynamic 
and Interventional Cardiology Laboratories of the 
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Cardiology Division of the Hospital das Clínicas in 
the Faculdade de Medicina of the Universidade de São 
Paulo in Ribeirão Preto will be selected. The patients 
must satisfy the following inclusion criteria: a) indica-
tion of exams due to chest pain, b) angiographically 
normal coronaries or coronaries without lesions > 30%, 
c) preserved global left ventricular systolic function or 
only mildly impaired function (left ventricular ejection 
fraction > 40%) and d) two positive serological tests 
for the diagnosis of Chagas disease using different 
methods (enzyme-linked immunosorbent assay [ELISA], 
haemaglutination or indirect immunofluorescence). 
After this initial selection, the patients who do not 
present initial exclusion criteria will sign an informed 
consent. The initial exclusion criteria are a history of 
diabetes mellitus, severe systemic arterial hyperten-
sion (light or moderate controlled degrees are accept-
able), heart rate < 60 bpm or systolic arterial pressure 
<  90  mmHg, and use of or clinical need for negative 
chronotropic drugs (cardiac glycoside, adrenergic beta-
blocker, or amiodarone). 
After signing the informed consent, the patients 
will be submitted to laboratory evaluation: electro-
cardiography, 24-hour Holter monitor, renal and liver 
function tests, total cholesterol fraction tests, and fasting 
blood glucose test for eventual detection of additional 
exclusion criteria:
 –  2nd and 3rd degree atrioventricular block;
 – Sick sinus syndrome;
 – Complex ventricular arrhythmia;
 – Alteration of liver function (serum albumin < 3 g/dL 
or total bilirubin > 1 mg/dL or prothrombin time 
>  25% of control); 
 – Alteration of renal function (creatinine >  1.4);
 – Diabetes mellitus (fasting blood glucose test 
>  126  mg/dL).
If there are no exclusion criteria, each patient will 
undergo a perfusion scintigraphy exam to detect revers-
ible perfusion defects, which will be the last inclusion 
criteria. Those presenting the mentioned alterations 
will be treated with 80  mg of verapamil twice a day 
+ 100 mg of acetylsalicylic acid for 90 days. After 90 
days, the perfusion myocardial scintigraphy will be 
repeated. 
The study outcomes will be verified 90 days after 
the beginning of treatment and will consist of: a primary 
outcome (reduction ≥ 50% of regional myocardial perfu-
sion alterations) and secondary outcome (disappearance 
or gradual relief of chest pain). 
Myocardial perfusion scintigraphy will be performed 
using the SPECT method with DST digital camera (Sopha 
Medical Vision – Twinsburg,, OH, USA) equipped with 
a dual detector, a rectangular vision field, a specific 
processor (NXT-P, Sopha Medical Vision), and a high-
resolution, low-energy collimator.
A stress test or vasodilator with dipyridamole will 
be used as a stressor. Technetium (99mTc) sestamibi will 
be used as a radiotracer to evaluate the regional myo-
cardial blood flow, with a dose of 12  mCi to 15  mCi 
at rest and 25  mCi to 30  mCi during the stress peak. 
Sample calculus
The sample calculus formula will be based on the 
following premises: 
1) The scintigraphic methods and analyses will be 
the same as those used in the study that resulted in the 
article published in 2009, which analysed a popula-
tion with Chagas disease with a profile similar to that 
predicted in this research;40 
2) The left ventricular area of reversible perfusion 
defects measured in scintigraphic polar maps will be 
approximately 10.2%, with s = 9.7% in relation to the 
total ventricular area;
3) With a two-tailed test of 0.05 and 1/β = 0.8, it 
is estimated that 63 patients will be necessary in order 
to detect at least a 50% reduction of the myocardial 
ischaemia area;
4) A 10% loss of patients was estimated between 
the first and second phases of the study; therefore, 
63/(1 – 0.1)  =  70 patients; 
5) Based on the aforementioned study, it is estimated 
that at least 56% of the patients initially considered will 
be part of the study after having verified the inclusion 
and exclusion criteria. To locate 70 patients with per-
fusion defects, it will be necessary to list 125 patients 
with the essential characteristics mentioned in this study. 
To detect the difference between the two means,45 
the sample formula was used: N  =  2.K.  s2  /  Δ2 in 
which N  =  number of patients, K  =  constant  =  7,849 
for the values of α and β defined above, s  = 9.7 and 
Δ  =  4.85  =  50% of 10.2. 
CONCLUSIONS
This will be the first therapeutic intervention study 
aimed at attenuating or reversing microvascular myo-
cardial ischemic alterations in patients with chronic 
Chagas disease.
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